Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
This study will evaluate the safety of a novel recombinant human papillomavirus bivalent (
 types 16 and 18 ) vaccine ( Yeast ) with different dose in healthy females between 9-45 years
 of age at enrollment.
Inclusion Criteria:

 -  Healthy female between, and including, 9 and 45 years of age at the time of the first
 vaccination

 -  Provide legal identification for for the sake of recruitment.

 -  Be able to understand and sign informed consent prior to enrollment (For subjects
 below the legal age of consent, informed consent must be signed by parent(s)/legal
 guardian(s) in addition).

 -  Subject must be not pregnant at the enrollment and agree to using adequate
 contraceptive precautions within 7 months.

 Exclusion Criteria:

 -  History of cervical cancer

 -  History of severe allergic reaction requiring medical intervention (such as oral and
 throat swelling, difficulty breathing, hypotension or shock)

 -  History of allergic to vaccine, or to any ingredient of vaccine.

 -  History of epilepsy, seizures or convulsions, or family history of mental illness

 -  Subjects are immunocompromised or have been diagnosed as suffering from congenital or
 acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus
 erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation
 (JRA), inflammatory bowel disease or other autoimmune diseases, administration of
 immunosuppressants with six months prior to the first vaccine dose.

 -  History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant

 -  Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy

 -  Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency,
 coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder

 -  Acute disease or chronic disease acute exacerbation 7 days prior to vaccination

 -  Administration of immunoglobulins and/or any blood products within 3 months, or
 administration of any live attenuated vaccine within 28 days, or administration of any
 subunit or inactivated vaccines within 14 days.

 -  Fever or axillary temperature> 37.0 °C before vaccination

 -  During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned
 pregnant within 7 month

 -  History of hypertension, physical examination systolic blood pressure> 150mmHg and/or
 diastolic blood pressure> 100mmHg

 -  Abnormal laboratory tests parameters

 -  Any clinical significant disease or findings during study screening that, in the
 opinion of the Investigator may interfere with the study